Key facts
- This page summarizes David Cunningham's Form 4 filing for IMMUCELL CORP /DE/ (ICCC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Jan 2023, 17:25.
David Cunningham - 15 Dec 2022 Form 4 Insider Report for IMMUCELL CORP /DE/ (ICCC)
- Reporting relationship
- Director
- Issuer ticker
- ICCC
- Reported as of
- 15 Dec 2022
- Net transaction value
- +$65,200
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2023, 17:25:50 UTC
- Prior SEC filing
- 14 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael F Brigham Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Cunningham filed Form 4 for IMMUCELL CORP /DE/ (ICCC) on 24 Jan 2023.
Change
- Previous filing in this sequence was filed on 14 Jun 2022.
- Current net transaction value: +$65,200.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ICCC
transaction
Derivative
Non Qualified Stock Options (Right to buy)
Award
- Transaction value
- $65,200
- Shares
- +10,000
- Change %
- Price
- $6.52
- Shares after
- 10,000
- Date
- 15 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $6.52
* marks a reported price that did not pass the local price check.